{
    "2018-07-18": [
        [
            {
                "time": "2018-07-18",
                "original_text": "Estimates and Recommendations for Eli Lilly on July 18",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "Estimates",
                        "Recommendations"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-07-18",
                "original_text": "Pfizer, Eli Lilly non-opioid pain drug nears finish line",
                "features": {
                    "keywords": [
                        "Pfizer",
                        "Eli Lilly",
                        "non-opioid",
                        "pain drug"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-07-18",
                "original_text": "Eli Lilly’s Q2 2018 Estimates: Expect Revenue Growth",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "Q2 2018",
                        "Revenue Growth"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-07-18",
                "original_text": "What to Expect from Eli Lilly and Company’s Q2 2018 Earnings",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "Q2 2018",
                        "Earnings"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-07-18",
                "original_text": "Pfizer-Lilly pain drug meets late-stage trial goals",
                "features": {
                    "keywords": [
                        "Pfizer",
                        "Lilly",
                        "pain drug",
                        "late-stage trial"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-07-18",
                "original_text": "Pfizer And Lilly Announce Positive Top-Line Results From Phase 3 Trial Of Tanezumab For The Treatment Of Osteoarthritis (OA) Pain",
                "features": {
                    "keywords": [
                        "Pfizer",
                        "Lilly",
                        "Tanezumab",
                        "Phase 3 Trial",
                        "Osteoarthritis Pain"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-07-18",
                "original_text": "Pfizer And Lilly Announce Positive Results From Phase 3 Trial Of Tanezumab",
                "features": {
                    "keywords": [
                        "Pfizer",
                        "Lilly",
                        "Tanezumab",
                        "Phase 3 Trial"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            }
        ]
    ]
}